The University of Oxford launched the first human trial of a vaccine against Bundibugyo ebolavirus on July 13, 2026, as the Democratic Republic of Congo battles an outbreak that's spreading faster than officials initially reported. The early-stage trial, known as BD-Ebov, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford. Recruitment has begun, with vaccinations expected to start in the coming weeks pending regulatory approval.
The timing matters. Congo's health authorities just confirmed the outbreak has reached two additional northeastern provinces—Haut-Uele and Tshopo—bringing the total confirmed cases to 1,926, including 702 deaths. Four cases were recorded in Tshopo, including two deaths, with one death confirmed in Haut-Uele, as of Saturday. Tshopo's provincial capital is Kisangani, one of Congo's largest cities. The spread into Haut-Uele, which shares borders with South Sudan and the Central African Republic, raises serious questions about containing the virus across an already unstable region.
The Vaccine Development Race
Oxford's Vaccine Group and Pandemic Sciences Institute developed the ChAdOx1 BDBV vaccine using the same viral vector platform as the Oxford/AstraZeneca COVID-19 shot. That's significant: it means the infrastructure and manufacturing knowledge already exist. Serum Institute of India, partnering on the program, manufactured and stockpiled about 620,000 doses of the vaccine candidate within two weeks and supplied 4,000 investigational doses for the early-stage study.
The Coalition for Epidemic Preparedness Innovations is backing this effort with up to $8.6 million in initial funding. In May 2026, the World Health Organization recommended prioritizing ChAdOx1 BDBV vaccine, alongside a single-dose candidate known as rVSV Bundibugyo being developed by the International AIDS Vaccine Initiative, for clinical evaluation as part of the response to the ongoing outbreak. That dual-track approach hedges risk—if one fails, the other moves forward.
Preparations are also under way for additional clinical studies in Uganda, subject to regulatory approval, through partnerships including the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit. If the early-stage trial succeeds, CEPI said it would work with Oxford and Serum Institute to support late-stage studies needed to seek emergency-use authorization or full regulatory approval. The partners said they aim to ensure rapid and affordable vaccine supplies for affected countries.
The Outbreak's True Scale Remains Unknown
Here's where the situation gets grimmer. Congo's latest Ebola outbreak, the country's 17th, was declared on May 15, 2026, and has been largely concentrated in Ituri province, with cases also reported in North Kivu and South Kivu provinces. But the National Institute of Public Health report dated July 11 acknowledged that "all cases detected in these two provinces are primarily imported from Niania in Ituri," yet the health system is still struggling to track spread.
A senior World Health Organization official told Reuters last week that the true scale of the outbreak could be two to four times larger than official data indicate because four out of five new Ebola cases have no known link to existing patients. That's alarming. It means the virus is spreading through channels authorities don't yet understand, and the 1,926 confirmed cases may represent only a fraction of actual infections.
Reuters reported in late June that Congolese health authorities had started tracing people potentially exposed to Ebola in Tshopo and Haut-Uele, but until now the two provinces had not been included in the government's daily reports. The virus spreads through direct contact with bodily fluids from infected people or animals and causes symptoms that can include high fever, vomiting and internal and external bleeding. It's often fatal, which is why the vaccine development timeline matters so much.
Why This Matters:
The Oxford trial represents a market-driven, private-sector-led response to a public health emergency. Rather than waiting for government bureaucracies to coordinate, Oxford, Serum Institute, and CEPI are moving at commercial speed—stockpiling 620,000 doses in two weeks and launching human trials within months of the outbreak declaration. This demonstrates how private pharmaceutical capacity and competitive innovation can outpace government health systems when given clear incentives and regulatory clarity. The outbreak's expansion into two new provinces and the WHO's acknowledgment that actual cases may be four times higher than reported underscores why rapid vaccine deployment matters. If the trial succeeds and regulatory approvals follow, the ability to manufacture and distribute doses affordably becomes the difference between containing spread and watching it metastasize across Central Africa. The fact that partners are already planning late-stage studies and emergency-use authorization pathways shows how institutional flexibility—not red tape—saves lives in a crisis.